Arbutus Biopharma (NASDAQ:ABUS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
Arbutus Biopharma GAAP EPS of -$0.04 misses by $0.01, revenue of $0.53M misses by $0.42M [Seeking Alpha]
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 [Yahoo! Finance]
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025